Hill Island Financial LLC Boosts Stock Holdings in Abbott Laboratories $ABT

Hill Island Financial LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 38.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,124 shares of the healthcare product maker’s stock after purchasing an additional 863 shares during the quarter. Hill Island Financial LLC’s holdings in Abbott Laboratories were worth $425,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of ABT. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the first quarter valued at $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at about $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories during the first quarter worth about $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories during the first quarter worth about $32,000. Finally, Vision Financial Markets LLC purchased a new position in Abbott Laboratories in the first quarter valued at about $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Up 1.1%

Shares of ABT stock opened at $134.49 on Friday. The company has a market capitalization of $234.07 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 2.55 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $131.94 and a 200 day moving average price of $131.36. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ABT shares. Leerink Partners initiated coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a report on Saturday, September 27th. Raymond James Financial cut their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research note on Friday, July 18th. BTIG Research lowered their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Finally, Royal Bank Of Canada lifted their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $145.39.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.